Primary breast non-Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

被引:66
作者
Validire, Patricia
Capovilla, Mathieu [2 ]
Asselain, Bernard [3 ]
Kirova, Youlia [4 ]
Goudefroye, Remi [2 ]
Plancher, Corine [3 ]
Fourquet, Alain [4 ]
Zanni, Manuela
Gaulard, Philippe [5 ]
Vincent-Salomon, Anne [2 ]
Decaudin, Didier [1 ,6 ]
机构
[1] Inst Curie, Serv Hematol Clin, Dept Clin Hematol, F-75248 Paris 05, France
[2] Inst Curie, Dept Tumor Biol, F-75248 Paris 05, France
[3] Inst Curie, Dept Biostat, F-75248 Paris 05, France
[4] Inst Curie, Dept Radiotherapy, F-75248 Paris 05, France
[5] Hop Henri Mondor, Dept Pathol, F-94010 Creteil, France
[6] Inst Curie, Translat Res Dept, Lab Preclin Invest, F-75248 Paris 05, France
关键词
B-CELL LYMPHOMA; BCL-2 PROTEIN EXPRESSION; RISK STRATIFICATION; RESPONSE CRITERIA; CHEMOTHERAPY; REARRANGEMENT; RITUXIMAB; PATTERNS; THERAPY; IMPACT;
D O I
10.1002/ajh.21353
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aims of this study were to define the initial pathological and clinical characteristics, and prognostic factors of patients with primary breast malignant lymphoma (PBL). All patients treated at the Institut Curie for lymphoma with breast involvement were reviewed. A pathological review of all cases was performed. Forty-five cases were selected in whom 38 cases were of diffuse large B-cell lymphoma. A complete analysis was then performed on these 38 patients. Twenty out of 28 cases (71%) of cases were Bcl-2 positive and four out of 28 (14%) had a CD10 positive staining. Peculiar initial characteristics showed nodal involvement in 58% of the cases and two or more extra-nodal sites in 31% of the cases. Among the 37 patients for whom all data were available, and according to the International Prognostic Index, 19 patients (51%) were classified in the low-risk group, 5 cases (14%) in the low- to intermediate-risk group, 6 patients (16%) in the intermediate- to high-risk group, and 7 (19%) case in the high-risk group. At the end of initial therapy, 34 patients (89%) achieved CR. With a median follow-up of 96 months, 18 patients (47%) relapsed of whom 3 had a relapse In central nervous system site. The 5-year disease-free (DFS) and overall survivals (OS) were 54% and 61%, respectively. In multivariate analysis, the presence of 2 or more extranodal sites was prognostic for lower DFS (P = 0.0008) and OS (P = 0.09), and a performance status >= 1 was prognostic for lower OS (P = 0.005). Finally, when our series was compared with a historical series of 111 patients with aggressive nodal lymphomas, we observed significant lower survival rates In localized PBL (P < 0.03). Initial breast localization has a pejorative Impact on the outcome of patients with Non-Hodgkin's Lymphoma (NHL), with an impressive adverse Influence of additional extranodal sites. These results suggest a specific management of NHL with breast involvement. Am. J. Hematol. 84:133-139, 2009. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 50 条
[1]   Primary diffuse large B-cell lymphoma of the breast a clinicopathologic study of 31 cases [J].
Abbondanzo, SL ;
Seidman, JD ;
Lefkowitz, M ;
Tavassoli, FA ;
Krishnan, J .
PATHOLOGY RESEARCH AND PRACTICE, 1996, 192 (01) :37-43
[2]   NON-HODGKINS-LYMPHOMA INVOLVING THE BREAST [J].
ARBER, DA ;
SIMPSON, JF ;
WEISS, LM ;
RAPPAPORT, H .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1994, 18 (03) :288-295
[3]  
ARIAD S, 1995, S AFR MED J, V85, P85
[4]   Rituximab and dose dense chemotherapy in primary breast lymphoma [J].
Aviles, Agustin ;
Castaneda, Claudia ;
Neri, Natividad ;
Cleto, Sergio ;
Jesus Nambo, M. .
HAEMATOLOGICA, 2007, 92 (08) :1147-1148
[5]   Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma [J].
Barrans, SL ;
Carter, I ;
Owen, RG ;
Davies, FE ;
Patmore, RD ;
Haynes, AP ;
Morgan, GJ ;
Jack, AS .
BLOOD, 2002, 99 (04) :1136-1143
[6]   Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis [J].
Berglund, M ;
Thunberg, U ;
Amini, RM ;
Book, M ;
Roos, G ;
Erlanson, M ;
Linderoth, J ;
Dictor, M ;
Jerkeman, M ;
Cavallin-Ståhl, E ;
Sundström, C ;
Rehn-Eriksson, S ;
Backlin, C ;
Hagberg, H ;
Rosenquist, R ;
Enblad, G .
MODERN PATHOLOGY, 2005, 18 (08) :1113-1120
[7]   CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses [J].
Biasoli, I ;
Morais, JC ;
Scheliga, A ;
Milito, CB ;
Romano, S ;
Land, M ;
Pulcheri, W ;
Spector, N .
HISTOPATHOLOGY, 2005, 46 (03) :328-333
[8]   Breast radiotherapy in the lateral decubitus position: A technique to prevent lung and heart irradiation [J].
Campana, F ;
Kirova, YM ;
Rosenwald, JC ;
Dendale, R ;
Vilcoq, JR ;
Dreyfus, H ;
Fourquet, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (05) :1348-1354
[9]  
CAO YB, 2007, ZI ZHENG, V26, P84
[10]  
CARBONE PP, 1971, CANCER RES, V31, P1860